Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002212
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
A Study of Targretin Capsules in Patients With AIDS-Related Kaposis Sarcoma
Sponsor:
Ligand Pharmaceuticals
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
Phase II Evaluation of Targretin Capsules in Patients With AIDS-Related Kaposis Sarcoma
Status:
COMPLETED
Status Verified Date:
1999-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposis sarcoma KS
Detailed Description:
This is a multicenter open-label study to evaluate the safety and efficacy of Targretin capsules in patients with AIDS-related KS NOTE The daily dose may be reduced as necessary for toxicity management
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| L1069-21 | None | None | None |